Organon & Co. Common Stock (NY:OGN)

10.16 +0.09 (+0.94%)
Streaming Delayed Price Updated: 11:41 AM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Organon & Co. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
3 Small-Cap Stocks Walking a Fine Line
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Bausch + Lomb, Organon, Globalstar, Telephone and Data Systems, and nLIGHT Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +1.5%) as President Trump postponed the planned 50% tariff on European Union imports,... 
Via StockStory
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
3 Low-Volatility Stocks with Questionable Fundamentals
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
OGN Q1 Earnings Call: Revenue Exceeds Expectations Amid Strategic Focus on Deleveraging and Product Growth
Pharmaceutical company Organon (NYSE:OGN) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 6.7% year on year to $1.51 billion. Its non-GAAP profit of $1.02 per... 
Via StockStory
Topics World Trade
Exposures Tariff
Earnings Scheduled For May 1, 2025
Via Benzinga
3 Value Stocks with Questionable Fundamentals
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
Organon Stock Tumbles To Record Low On Downgrades And Dividend Cut: Retail Optimism Persists
Organon shares sank 27% Thursday after slashing its dividend by over 90%, triggering analyst downgrades and investor concern. Some retail traders, however, remained upbeat, citing the company’s focus... 
Via Stocktwits
Topics World Trade
Exposures Tariff
Here are the top movers in Thursday's session.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Top stock movements in today's session.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Dow Surges Over 300 Points; McDonald's Posts Weak Revenue
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
The market is filled with gapping stocks in Thursday's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday. 
Via Chartmill
These stocks are moving in today's pre-market session
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
Organon (NYSE:OGN) Posts Better-Than-Expected Sales In Q1 But Stock Drops 23.5%
Pharmaceutical company Organon (NYSE:OGN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 6.7% year on year to $1.51 billion. Its non-GAAP profit of $1.02 per share... 
Via StockStory
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Organon (OGN) Q1 Earnings: What To Expect
Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
Exposures Artificial Intelligence Economy Tariff
3 Cash-Producing Stocks with Questionable Fundamentals
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
LGI Homes, Super Micro, Organon, Ibotta, and ManpowerGroup Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after investor sentiment improved on renewed optimism that the US-China trade conflict might be nearing a resolution. According to reports, Treasury... 
Via StockStory
Topics World Trade
Exposures Tariff
Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Organon (OGN): Buy, Sell, or Hold Post Q4 Earnings?
Organon has gotten torched over the last six months - since October 2024, its stock price has dropped 29.4% to a new 52-week low of $12.79 per share. This was partly driven by its softer quarterly... 
Via StockStory
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
3 Small-Cap Stocks Skating on Thin Ice
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
1 Healthcare Stock with Solid Fundamentals and 2 to Turn Down
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
High-Yield Healthcare: 3 Stocks With Strong Dividends
This article covers three healthcare stocks that offer dividend yields of at least 7% and dives deeper into the fundamentals to determine if they're good buys. 
Via MarketBeat
Organon (OGN) Shares Skyrocket, What You Need To Know
Shares of pharmaceutical company Organon (NYSE:OGN) jumped 12.5% in the morning session after the company reported fourth-quarter 2024 results that topped analysts' revenue and EPS expectations. While... 
Via StockStory
Topics Initial Public Offering
Exposures Securities Market
Organon (NYSE:OGN) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations Significantly
Pharmaceutical company Organon (NYSE:OGN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales were flat year on year at $1.59 billion. On the other hand, the company’s... 
Via StockStory
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.